arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Savara Inc

SVRA
$5.01 ▼ -0.29 (-5.38%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Poor
Neutral
auto_awesome

Analytical Summary

Savara Inc shows mixed fundamentals. On the positive side, Debt to Equity remains strong. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.1B
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -53.0% →
FCF / Share $-0.45 →
Trailing P/E —
Price / Book 5.1x
FCF Yield —
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$257.00K
— —
Net Income Profit after all expenses
$-118.84M
↓ -23.9% —
FCF / Share Free cash flow per share
$-0.45
↓ -1.1% —
Long-Term Debt Long-term obligations
$29.91M
↑ +12.4% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
15
Financial Health →
48
Cash Quality ↓
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 31 years · 82 quarters